SRP 299
Alternative Names: SR299; SRP299Latest Information Update: 16 May 2007
Price :
$50 *
At a glance
- Originator SR Pharma
- Developer Genesis Research and Development
- Class Adjuvants; Antiallergics; Antiasthmatics; Skin disorder therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic asthma; Atopic dermatitis
Most Recent Events
- 31 Dec 2004 Discontinued - Phase-II for Atopic dermatitis in Ireland (Intradermal)
- 31 Dec 2004 Discontinued - Phase-II for Atopic dermatitis in United Kingdom (Intradermal)
- 04 Jun 2004 SRP 299 or AVAC will be available for licensing on the completion of current phase II trials (http://www.genesis.co.nz)